Molecular models of N-Benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-δ

Journal of Medicinal Chemistry

Volumn 44, Issue 7, 2001, Pages 1028-1034

  Roaten, J B ^a   Kazanietz, M G ^b   Sweatman, T W ^a   Lothstein, L ^a   Israel, M ^a   Parrill, A L ^c  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Memphis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTHRACYCLINE DERIVATIVE; BETA2 CHIMERIN; CARBONYL DERIVATIVE; CHIMERIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; N BENZYLDOXORUBICIN 14 VALERATE; PHORBOL DIBUTYRATE; PHORBOL ESTER; PROTEIN KINASE C; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; FIBROBLAST; HYDROGEN BOND; IN VITRO STUDY; MOLECULAR INTERACTION; MOLECULAR MODEL; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN STABILITY; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION;

ANTIBIOTICS, ANTINEOPLASTIC; CAENORHABDITIS ELEGANS PROTEINS; DOXORUBICIN; ISOENZYMES; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN KINASE C; PROTEIN KINASE C-DELTA; RECEPTORS, DRUG;

EID: 0035966870     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000289v     Document Type: Article

References (40)

1. Critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
2. Amelioration of adriamycin toxicity through modification of drug-DNA binding properties
3. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA
4. Cytotoxicity and intracellular biotransformation of N-Benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length
5. Activity of N-Benzyladriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines
6. N-Benzyladriamycin-14-valerate and drug resistance: Correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant
7. Cytotoxicity and cellular pharmacology of N-Benzyladriamycin-14-valerate in mechanistically different multidrug-resistant human leukemia cells
8. Pharmacology of N-Benzyladriamycin-14-valerate in the rat
9. Crystal structure of the Cys2 activator-binding domain of protein kinase Cδ in complex with phorbol ester
10. Residues in the second cysteine-rich region of protein kinase C δ relevant to phorbol ester binding as revealed by site-directed mutagenesis
11. Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C
12. Beta2-chimaerin is a novel target for diacylglycerol: Binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain
13. Clarification of the binding mode of teleocidin and benzolactams to the Cys2 domain of protein kinase C delta by synthesis of hydrophobically modified, teleocidin-mimicking benzolactams and computational docking simulation
14. Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C?
15. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules
16. Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCδ and discovery of an ILV analogue of improved isozyme selectivity
17. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts
18. 3H]phorbol 12,13-dibutyrate binding
19. Calcium-independent binding to interfacial phorbol esters causes protein kinase C to associate with membranes in the absence of acidic lipids
20. Mechanism of interaction of protein kinase C with phorbol esters. Reversibility and nature of membrane association
21. Protein kinase C and phospholipase C: Bilayer interactions and regulation
22. The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands
23. A fluorescence study examining how 14-valerate side chain substitution modulates anthracycline binding to small unilamellar phospholipid vesicles
24. Interaction of N-alkylanthracyclines with lipid bilayers: Correlations between partition coefficients, lipid phase distributions and thermotropic behavior
25. Analysis of the phorbol ester pharmacophore on protein kinase C as a guide to the rational design of new classes of analogues
26. Structural basis of protein kinase C activation by tumor promoters
27. The pharmacophore of debromoaplysiatoxin responsible for protein kinase C activation
28. Structure/activity relationships of polyfunctional diterpenes of the tigliane type. A pharmacophore model for protein-kinase-C activators based on structure/activity studies and molecular modeling of the tumor promoters 12-O-tetradecanoylphorbol 13-acetate and 3-O-tetradecanoylingenol
29. Protein kinase C ligands based on tetrahydrofuran templates containing a new set of phorbol ester pharmacophores
30. Polar molecular surface properties predict the intestinal absorption of drugs in humans
31. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption
32. Low affinity binding of phorbol esters to protein kinase C and its recombinant cystein-rich region in the absence of phospholipids
33. Interplay of C1 and C2 domains of protein kinase C-alpha in its membrane binding and activation